Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/1/2026 | $50.00 | Overweight | Cantor Fitzgerald |
| 2/27/2026 | $48.00 | Overweight | Piper Sandler |
| 12/3/2025 | $50.00 | Buy | Lake Street |
| 12/3/2025 | $60.00 | Buy | H.C. Wainwright |
| 11/25/2025 | $57.00 | Buy | Roth Capital |
| 9/2/2025 | $50.00 | Outperform | Oppenheimer |
DURHAM, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs, ("Pelthos"), today announced that CEO Scott Plesha will present at 11:05 am ET and participate in one-on-one investor meetings at the Jefferies Global Healthcare Conference on June 4, 2026 in New York. Investors interested in arranging one-on-one meetings should contact their Jefferies representative. About Pelthos Therapeutics Pelthos Therapeutics is a commercial-stage biopharmaceutical company focused on building and advancing a portfolio of differentiated cutaneous infectious disease prod
ZELSUVMI® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for the first quarter of 2026, with a 25% quarter over quarter increase in units dispensed Management will host a conference call today, May 14, 2026, at 8:30 a.m. ET DURHAM, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos," "we" or the "Company"), today announced its financial results for the first quarter ended March 31,
DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it will report first quarter 2026 financial results on Thursday, May 14, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern time. Details for the conference call can be found below: Date: Thursday, May 14, 2026Time: 8:30 a.m. Eastern TimeToll Free: 1-877-451-6152International: 1-201-389-0879Conf. ID: 13760399 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1761761&tp_key=d31924f2e0 About Peltho
Cantor Fitzgerald initiated coverage of Pelthos Therapeutics Inc. with a rating of Overweight and set a new price target of $50.00
Piper Sandler initiated coverage of Pelthos Therapeutics Inc. with a rating of Overweight and set a new price target of $48.00
Lake Street initiated coverage of Pelthos Therapeutics Inc. with a rating of Buy and set a new price target of $50.00
4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
4 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
3 - Pelthos Therapeutics Inc. (0001919246) (Issuer)
8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
144 - Pelthos Therapeutics Inc. (0001919246) (Subject)
8-K - Pelthos Therapeutics Inc. (0001919246) (Filer)
DURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it has named veteran finance executive Andrew J. Einhorn to its Board of Directors effective immediately. Mr. Einhorn will serve on the Board of Directors until Pelthos' 2026 annual meeting of shareholders and until his successor is elected and qualified or until his earlier resignation or removal. Also, effective immediately, Mr. Einhorn will also serve on the Audit Committee and the Compensation Committee of the Pelthos Board of Directors. Mr. Einhorn brings ext
The Moms Against Molluscum movement aims to empower families impacted by molluscum to share their personal stories and encourage others to join the conversationMolluscum is a highly contagious skin infection affecting 16.7 million Americans, mainly childrenMomsAgainstMolluscum.com will offer new resources to support moms, parents, and other caregivers of molluscum patients DURHAM, N.C., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced the launch of Moms Against Molluscum, a movement to unite mothers, parents, and other careg
Files Quarterly Report on Form 10-Q detailing financial results for legacy operations for the three and six months ended June 30, 2025Strong physician response following successful launch of ZELSUVMI™ (berdazimer) topical gel 10.3%, the first and only FDA-approved at-home treatment for molluscum contagiosum for patients one year of age and olderCompletes build-out of essential management operational infrastructure and hires 50 territory sales managers DURHAM, N.C., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company ("Pelthos" or the "Company") committed to commercializing innovative therapeutic products for high unmet patient nee
ZELSUVMI® net product revenue grew 17% quarter over quarter from $9.1 million in the fourth quarter of 2025 to $10.7 million in the first quarter of 2026 7,884 ZELSUVMI units prescribed by 3,228 unique prescribers for the first quarter of 2026, with a 25% quarter over quarter increase in units dispensed Management will host a conference call today, May 14, 2026, at 8:30 a.m. ET DURHAM, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos," "we" or the "Company"), today announced its financial results for the first quarter ended March 31,
DURHAM, N.C., May 01, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it will report first quarter 2026 financial results on Thursday, May 14, 2026. The company will hold a conference call followed by a question-and-answer period at 8:30 a.m. Eastern time. Details for the conference call can be found below: Date: Thursday, May 14, 2026Time: 8:30 a.m. Eastern TimeToll Free: 1-877-451-6152International: 1-201-389-0879Conf. ID: 13760399 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1761761&tp_key=d31924f2e0 About Peltho
ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025. 8,948 ZELSUVMI units prescribed by 2,712 unique prescribers for fiscal year 2025, with a 129% quarter over quarter increase in units dispensed, rising from 2,716 units in the third quarter of 2025 to 6,232 units in the fourth quarter of 2025. Management will host a conference call today at 8:00 a.m. EDT DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE:PTHS), a biopharmace